Furthermore, CAR T cells, composed of MOv19 anti-FRα-specific single chain variable fragment fused to 4-1BB and TCRzeta signaling domains (MOv19-BBZ), is currently evaluated by a phase I clinical trial in recurrent high grade serous ovarian cancer patients (78). The gene discussed is FOLR1; the disease is ovarian serous adenocarcinoma.